Hydroxychloroquine Sulfate 200 MG

DRUG4 trials

Sponsors

RedHill Biopharma Limited, Sir Mortimer B. Davis - Jewish General Hospital, Shaheed Zulfiqar Ali Bhutto Medical University, Cambridge University Hospitals NHS Foundation Trust

Conditions

COVID 19COVID-19CholangiocarcinomaCholangiocarcinoma Non-resectableCholangiocarcinoma, ExtrahepaticCholangiocarcinoma, IntrahepaticCholangiocarcinoma, PerihilarHydroxychloroquine

Phase 2

A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma

CompletedNCT03377179

RedHill Biopharma LimitedCholangiocarcinoma, Cholangiocarcinoma, Extrahepatic, Cholangiocarcinoma, Intrahepatic +2

Start: 2018-03-07End: 2022-06-21Updated: 2025-07-23

Effect of Hydroxychloroquine in COVID-19 Positive Pregnant Women

WithdrawnNCT04354441

Sir Mortimer B. Davis - Jewish General HospitalCOVID-19, Hydroxychloroquine, Pregnant Women +1

Start: 2020-05-31End: 2020-05-31Updated: 2020-06-25

Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID 19

Shaheed Zulfiqar Ali Bhutto Medical UniversityCOVID 19

Start: 2020-05-01End: 2020-09-25Target: 200Updated: 2020-05-19

PROphylaxis for paTiEnts at Risk of COVID-19 infecTion

WithdrawnNCT04389359

Cambridge University Hospitals NHS Foundation TrustCOVID-19

Start: 2020-09-30End: 2025-08-31Updated: 2021-03-08